Eur Heart J:高血压靶器官损害可预测糖尿病

2013-07-29 高晓方 译 cmt

意大利一项研究表明,在接受治疗的高血压患者中,初始左室肥大(LVH)和颈动脉粥样硬化(CA)为新发糖尿病的显著预测因素,且独立于初始代谢水平、抗高血压治疗及其他显著协变量。论文于7月23日在线发表于《欧洲心脏杂志》(Eur Heart J)。 此项研究共纳入4176例基线未伴糖尿病的高血压患者,并进行了≥1年的随访(中位3.57年)。患者平均年龄为58.7 ± 8.9岁,男性

意大利一项研究表明,在接受治疗的高血压患者中,初始左室肥大(LVH)和颈动脉粥样硬化(CA)为新发糖尿病的显著预测因素,且独立于初始代谢水平、抗高血压治疗及其他显著协变量。论文于7月23日在线发表于《欧洲心脏杂志》(Eur Heart J)。

此项研究共纳入4176例基线未伴糖尿病的高血压患者,并进行了≥1年的随访(中位3.57年)。患者平均年龄为58.7 ± 8.9岁,男性占58%。以左室质量指数(LVMi)≥51 g/m2.7定义LVH,以内中膜厚度>1.5 mm定义CA。

结果显示,随访期间共有393例(9.4%)患者出现糖尿病;在初始伴LVH或CA的患者中糖尿病发生率较高(P<0.0001)。Cox回归显示,初始存在LVH或CA与糖尿病高风险具有相关性(HR=1.30和1.38,P值均为0.03),并且独立于所用降压药类型和数量、初始收缩压、体重指数、空腹血糖、糖尿病家族史(P值均< 0.0001)和β阻滞剂治疗。临床前心血管疾病标志物之一或二者均出现可使糖尿病发生机率升高63%或64%(P值均< 0.002),独立于显著的混杂因素。

Izzo R, de Simone G, Trimarco V, Gerdts E, Giudice R, Vaccaro O, De Luca N, Trimarco B.Hypertensive target organ damage predicts incident diabetes mellitus.Eur Heart J. 2013 Jul 23. [Epub ahead of print]PMID:23882068

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1822356, encodeId=cc7f1822356a6, content=<a href='/topic/show?id=4eb3102e1909' target=_blank style='color:#2F92EE;'>#高血压靶器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102719, encryptionId=4eb3102e1909, topicName=高血压靶器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Mar 28 11:56:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078430, encodeId=51a120e8430d6, content=<a href='/topic/show?id=4d92999582c' target=_blank style='color:#2F92EE;'>#靶器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99958, encryptionId=4d92999582c, topicName=靶器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Jun 09 03:56:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693895, encodeId=f9cb169389550, content=<a href='/topic/show?id=48a140299ae' target=_blank style='color:#2F92EE;'>#器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40299, encryptionId=48a140299ae, topicName=器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdcd29484210, createdName=lujian, createdTime=Mon Dec 02 00:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355783, encodeId=40ed1355e83ad, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562180, encodeId=869f15621805f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1822356, encodeId=cc7f1822356a6, content=<a href='/topic/show?id=4eb3102e1909' target=_blank style='color:#2F92EE;'>#高血压靶器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102719, encryptionId=4eb3102e1909, topicName=高血压靶器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Mar 28 11:56:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078430, encodeId=51a120e8430d6, content=<a href='/topic/show?id=4d92999582c' target=_blank style='color:#2F92EE;'>#靶器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99958, encryptionId=4d92999582c, topicName=靶器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Jun 09 03:56:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693895, encodeId=f9cb169389550, content=<a href='/topic/show?id=48a140299ae' target=_blank style='color:#2F92EE;'>#器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40299, encryptionId=48a140299ae, topicName=器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdcd29484210, createdName=lujian, createdTime=Mon Dec 02 00:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355783, encodeId=40ed1355e83ad, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562180, encodeId=869f15621805f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]
    2014-06-09 habb
  3. [GetPortalCommentsPageByObjectIdResponse(id=1822356, encodeId=cc7f1822356a6, content=<a href='/topic/show?id=4eb3102e1909' target=_blank style='color:#2F92EE;'>#高血压靶器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102719, encryptionId=4eb3102e1909, topicName=高血压靶器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Mar 28 11:56:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078430, encodeId=51a120e8430d6, content=<a href='/topic/show?id=4d92999582c' target=_blank style='color:#2F92EE;'>#靶器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99958, encryptionId=4d92999582c, topicName=靶器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Jun 09 03:56:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693895, encodeId=f9cb169389550, content=<a href='/topic/show?id=48a140299ae' target=_blank style='color:#2F92EE;'>#器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40299, encryptionId=48a140299ae, topicName=器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdcd29484210, createdName=lujian, createdTime=Mon Dec 02 00:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355783, encodeId=40ed1355e83ad, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562180, encodeId=869f15621805f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1822356, encodeId=cc7f1822356a6, content=<a href='/topic/show?id=4eb3102e1909' target=_blank style='color:#2F92EE;'>#高血压靶器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102719, encryptionId=4eb3102e1909, topicName=高血压靶器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Mar 28 11:56:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078430, encodeId=51a120e8430d6, content=<a href='/topic/show?id=4d92999582c' target=_blank style='color:#2F92EE;'>#靶器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99958, encryptionId=4d92999582c, topicName=靶器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Jun 09 03:56:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693895, encodeId=f9cb169389550, content=<a href='/topic/show?id=48a140299ae' target=_blank style='color:#2F92EE;'>#器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40299, encryptionId=48a140299ae, topicName=器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdcd29484210, createdName=lujian, createdTime=Mon Dec 02 00:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355783, encodeId=40ed1355e83ad, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562180, encodeId=869f15621805f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]
    2013-07-31 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1822356, encodeId=cc7f1822356a6, content=<a href='/topic/show?id=4eb3102e1909' target=_blank style='color:#2F92EE;'>#高血压靶器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102719, encryptionId=4eb3102e1909, topicName=高血压靶器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Fri Mar 28 11:56:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078430, encodeId=51a120e8430d6, content=<a href='/topic/show?id=4d92999582c' target=_blank style='color:#2F92EE;'>#靶器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99958, encryptionId=4d92999582c, topicName=靶器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Jun 09 03:56:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693895, encodeId=f9cb169389550, content=<a href='/topic/show?id=48a140299ae' target=_blank style='color:#2F92EE;'>#器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40299, encryptionId=48a140299ae, topicName=器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdcd29484210, createdName=lujian, createdTime=Mon Dec 02 00:56:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355783, encodeId=40ed1355e83ad, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562180, encodeId=869f15621805f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 31 07:56:00 CST 2013, time=2013-07-31, status=1, ipAttribution=)]
    2013-07-31 slcumt

相关资讯

以“阵发性心慌”为表现的一例老人患者

  典型病例   患者男,65岁,因“阵发性心慌”就诊。患者有高血压病史10年,规律服用氨氯地平5 mg/d,血压控制满意;乙肝病毒(HBV)感染病史30年,肝功能正常;2年前单位体检发现血糖略高,其余检查未见异常。无烟酒等嗜好。家族中父亲患食管癌,母亲患高血压,其兄患肺癌。平日体力活动正常、生活完全自理。近期独居。   入院检查   体胖,面色发黑,肝掌,

PLoS One:我国20岁以上成年人高血压患病率高达26.6%

6月11日,北京中日友好医院杨文英教授等公布的2007-2008年中国糖尿病和代谢紊乱研究最新数据显示,我国20岁以上成年人中,高血压患病率高达26.6%,即高血压患病人数达2.54 亿, 其中20~44岁年轻人和农村人群中高血压患病率增长快。而据2002年调查数据,我国18 岁以上成年人中,高血压患病率为18.8%。该研究结果发表在《公共科学图书馆在线杂志》上[PLoS One. 2013, 8

ESH高血压管理指南深度解读:领悟精髓 择善而从

在意大利米兰召开的欧洲高血压学会(ESH)第23届科学年会上,ESH与欧洲心脏病学会(ESC)共同发布了《动脉高血压管理指南》。这无疑成为本次会议的最大亮点之一。中国医学科学院阜外心血管病医院张宇清教授对该指南的更新要点进行了深度解析,使我们能全方位的了解指南精髓内容。 张宇清教授在ESH会场1、新版指南更新特点宗旨不变,注重教育性与前2版指南一致的是,新版指南仍然强调其是一部教育性的指

2013 ESH 高血压指南的18个更新要点

2013 欧洲高血压学会(ESH)/欧洲心脏病学会(ESC)高血压管理指南(2013 EHRA/ESC 心脏起搏器和心脏再同步化治疗指南 )(以下简称“新版指南”)延续了前两版指南的一些基本原则,即:①通过广泛复习文献,选择恰当的研究作为推荐基础;②随机对照研究及其荟萃分析作为最高等级优先选择,但不排除观察性研究和其他的适当的科学研究结果,尤其在诊断方面;③首次提出证据等级和推荐强度,从而使得临床

孙宁玲:欧洲高血压指南的一些新理念

孙宁玲教授介绍了2013年欧洲高血压指南的重要改变及对我国指南修订产生的影响。详细内容如下:孙宁玲教授:ESH2013年会是在意大利米兰召开的,米兰是欧洲高血压重要的中心,欧洲高血压年会也是在那创建的,好几任大会主席都是在那诞生的,所以米兰的高血压防治工作做得比较好。那么,今年ESH年会最大的亮点就是发布了2013 EHRA/ESC 心脏起搏器和心脏再同步化治疗指南 。我对这个指南有自己的几点思考

张宇清:从2013 ESH指南看SPC在降压治疗中的地位

欧洲高血压学会/欧洲心脏病学会(ESH/ESC)高血压治疗指南一直是世界上被引用最多的医学文献之一,第一版指南问世于10年前。这10年是高血压防治研究快速发展的10年,在许多方面都取得了新的进展。2013年,ESH/ESC工作组回顾了自上次修订版(2007年)以来的所有相关数据,对高血压的治疗做出了科学推荐,发布了ESH/ESC 2013动脉高血压管理指南 。中国医学科学院阜外心血管病医院的张宇清